Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab added to induction chemotherapy in older adults with AML or high-risk MDS
NL-OMON29842Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by HOVON. Primary endpoints: Dose-limiting toxicity incidence and Complete remission rate. Started Feb 2007; status: active, not recruiting.
02
Drugs
bevacizumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON29842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON29842.